CORCEPT THERAPEUTICS INC (CORT) Stock Fundamental Analysis
NASDAQ:CORT - Nasdaq - US2183521028 - Common Stock - Currency: USD
We assign a fundamental rating of 7 out of 10 to CORT. CORT was compared to 194 industry peers in the Pharmaceuticals industry. CORT scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CORT is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make CORT suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year CORT was profitable.
CORT had a positive operating cash flow in the past year.
In the past 5 years CORT has always been profitable.
CORT had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 15.83%, CORT belongs to the best of the industry, outperforming 97.42% of the companies in the same industry.
CORT has a Return On Equity of 19.61%. This is amongst the best in the industry. CORT outperforms 92.78% of its industry peers.
The Return On Invested Capital of CORT (13.61%) is better than 90.72% of its industry peers.
CORT had an Average Return On Invested Capital over the past 3 years of 17.94%. This is above the industry average of 14.87%.
The 3 year average ROIC (17.94%) for CORT is well above the current ROIC(13.61%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.83% | ||
| ROE | 19.61% | ||
| ROIC | 13.61% |
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
1.3 Margins
CORT has a better Profit Margin (19.55%) than 93.30% of its industry peers.
In the last couple of years the Profit Margin of CORT has declined.
The Operating Margin of CORT (16.17%) is better than 85.05% of its industry peers.
CORT's Operating Margin has declined in the last couple of years.
CORT's Gross Margin of 98.43% is amongst the best of the industry. CORT outperforms 98.45% of its industry peers.
CORT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.17% | ||
| PM (TTM) | 19.55% | ||
| GM | 98.43% |
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CORT is creating some value.
The number of shares outstanding for CORT has been increased compared to 1 year ago.
CORT has less shares outstanding than it did 5 years ago.
There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CORT has an Altman-Z score of 30.22. This indicates that CORT is financially healthy and has little risk of bankruptcy at the moment.
CORT has a Altman-Z score of 30.22. This is amongst the best in the industry. CORT outperforms 94.33% of its industry peers.
CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 30.22 |
ROIC/WACC1.34
WACC10.12%
2.3 Liquidity
A Current Ratio of 3.07 indicates that CORT has no problem at all paying its short term obligations.
CORT has a Current ratio (3.07) which is in line with its industry peers.
A Quick Ratio of 2.96 indicates that CORT has no problem at all paying its short term obligations.
CORT has a Quick ratio (2.96) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.07 | ||
| Quick Ratio | 2.96 |
3. Growth
3.1 Past
CORT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.43%, which is quite good.
The Earnings Per Share has been growing by 9.71% on average over the past years. This is quite good.
CORT shows a strong growth in Revenue. In the last year, the Revenue has grown by 30.93%.
The Revenue has been growing by 17.11% on average over the past years. This is quite good.
EPS 1Y (TTM)9.43%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-32%
Revenue 1Y (TTM)30.93%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%7.09%
3.2 Future
CORT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 56.00% yearly.
The Revenue is expected to grow by 30.41% on average over the next years. This is a very strong growth
EPS Next Y13.31%
EPS Next 2Y47.92%
EPS Next 3Y70.13%
EPS Next 5Y56%
Revenue Next Year29.79%
Revenue Next 2Y32.48%
Revenue Next 3Y32.46%
Revenue Next 5Y30.41%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 61.09, the valuation of CORT can be described as expensive.
CORT's Price/Earnings ratio is a bit cheaper when compared to the industry. CORT is cheaper than 79.38% of the companies in the same industry.
CORT is valuated expensively when we compare the Price/Earnings ratio to 27.54, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 26.12, CORT can be considered very expensive at the moment.
70.10% of the companies in the same industry are more expensive than CORT, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.44, CORT is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 61.09 | ||
| Fwd PE | 26.12 |
4.2 Price Multiples
76.80% of the companies in the same industry are more expensive than CORT, based on the Enterprise Value to EBITDA ratio.
CORT's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CORT is cheaper than 79.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 42.41 | ||
| EV/EBITDA | 61.79 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
CORT has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as CORT's earnings are expected to grow with 70.13% in the coming years.
PEG (NY)4.59
PEG (5Y)6.29
EPS Next 2Y47.92%
EPS Next 3Y70.13%
5. Dividend
5.1 Amount
CORT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
70.86
-2.24 (-3.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners79.51%
Inst Owner Change-0.55%
Ins Owners6.55%
Ins Owner Change0.39%
Market Cap7.51B
Analysts82
Price Target141.01 (99%)
Short Float %12.2%
Short Ratio7.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.62%
Min EPS beat(2)-40.2%
Max EPS beat(2)16.96%
EPS beat(4)3
Avg EPS beat(4)13.93%
Min EPS beat(4)-40.2%
Max EPS beat(4)42.54%
EPS beat(8)7
Avg EPS beat(8)20.33%
EPS beat(12)9
Avg EPS beat(12)10.46%
EPS beat(16)12
Avg EPS beat(16)11.02%
Revenue beat(2)0
Avg Revenue beat(2)-11.81%
Min Revenue beat(2)-13.38%
Max Revenue beat(2)-10.25%
Revenue beat(4)2
Avg Revenue beat(4)-4.03%
Min Revenue beat(4)-13.38%
Max Revenue beat(4)4.07%
Revenue beat(8)6
Avg Revenue beat(8)-0.63%
Revenue beat(12)7
Avg Revenue beat(12)-1.42%
Revenue beat(16)8
Avg Revenue beat(16)-1.72%
PT rev (1m)0%
PT rev (3m)-2.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-50.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-18.73%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.98%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)-0.7%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 61.09 | ||
| Fwd PE | 26.12 | ||
| P/S | 10.96 | ||
| P/FCF | 42.41 | ||
| P/OCF | 41.87 | ||
| P/B | 11 | ||
| P/tB | 11 | ||
| EV/EBITDA | 61.79 |
EPS(TTM)1.16
EY1.64%
EPS(NY)2.71
Fwd EY3.83%
FCF(TTM)1.67
FCFY2.36%
OCF(TTM)1.69
OCFY2.39%
SpS6.46
BVpS6.44
TBVpS6.44
PEG (NY)4.59
PEG (5Y)6.29
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.83% | ||
| ROE | 19.61% | ||
| ROCE | 15.76% | ||
| ROIC | 13.61% | ||
| ROICexc | 25.27% | ||
| ROICexgc | 25.27% | ||
| OM | 16.17% | ||
| PM (TTM) | 19.55% | ||
| GM | 98.43% | ||
| FCFM | 25.85% |
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
ROICexc(3y)74.13%
ROICexc(5y)85.06%
ROICexgc(3y)74.13%
ROICexgc(5y)85.06%
ROCE(3y)20.79%
ROCE(5y)23.98%
ROICexcg growth 3Y-18.86%
ROICexcg growth 5Y-17.58%
ROICexc growth 3Y-18.86%
ROICexc growth 5Y-17.58%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
F-Score6
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 159.44% | ||
| Profit Quality | 132.22% | ||
| Current Ratio | 3.07 | ||
| Quick Ratio | 2.96 | ||
| Altman-Z | 30.22 |
F-Score6
WACC10.12%
ROIC/WACC1.34
Cap/Depr(3y)72.82%
Cap/Depr(5y)100.78%
Cap/Sales(3y)0.15%
Cap/Sales(5y)0.19%
Profit Quality(3y)125.51%
Profit Quality(5y)133.52%
High Growth Momentum
Growth
EPS 1Y (TTM)9.43%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-32%
EPS Next Y13.31%
EPS Next 2Y47.92%
EPS Next 3Y70.13%
EPS Next 5Y56%
Revenue 1Y (TTM)30.93%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%7.09%
Revenue Next Year29.79%
Revenue Next 2Y32.48%
Revenue Next 3Y32.46%
Revenue Next 5Y30.41%
EBIT growth 1Y-9.1%
EBIT growth 3Y3.23%
EBIT growth 5Y4.18%
EBIT Next Year20.41%
EBIT Next 3Y47.8%
EBIT Next 5Y19.15%
FCF growth 1Y60.04%
FCF growth 3Y5.38%
FCF growth 5Y7.73%
OCF growth 1Y61.51%
OCF growth 3Y5.66%
OCF growth 5Y7.79%